Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA
J Clin Oncol. 2003 21 (16): 3133-40

PMID: 12810695 · DOI:10.1200/JCO.2003.02.014

MeSH Terms (11)

Adjuvants, Immunologic Adult Carcinoma, Renal Cell Disease-Free Survival Female Humans Interleukin-2 Kidney Neoplasms Male Middle Aged Survival Analysis

Connections (1)

This publication is referenced by other Labnodes entities:

Links